CoChat

From "serum sickness" to "xenosialitis": past, present, and future significance of the non-human sialic acid Neu5Gc

Dhar, Chirag, Sasmal, Aniruddha, Varki, Ajit · 2019 · Frontiers in Immunology
Cited by 123

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2019.00807

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 175

  1. Jackson, 2000, Serum sickness, J Cutan Med Surg., 4, 223, 10.1177/120347540000400411 · doi:10.1177/120347540000400411
  2. Bolton, 1899, The complications of the serum treatment of diptheria, Lancet., 153, 891, 10.1016/S0140-6736(01)68368-5 · doi:10.1016/s0140-6736(01)68368-5
  3. Pirquet, 1905, Die Serumkrankheit.
  4. Hanganutziu, 1924, Hémagglutinines hétérogénétiques après injection de sérum de cheval, CR Séances Soc Biol., 91, 1457
  5. Deicher, 1926, Über die Erzeugung heterospezifischer Hämagglutinine durch Injektion artfremden, Serums Z Hyg., 106, 561, 10.1007/BF02176298 · DOI
  6. Kasukawa, 1976, Heterophile antibodies in pathologic human sera resembling antibodies stimulated by foreign species sera, Clin Exp Immunol., 25, 122
  7. Higashi, 1977, Antigen of “serum sickness” type of heterophile antibodies in human sera: indentification as gangliosides with N-glycolylneuraminic acid, Biochem Biophys Res Commun., 79, 388, 10.1016/0006-291X(77)90169-3 · DOI · Paper page
  8. Merrick, 1978, Characterization of the hanganutziu-deicher (serum-sickness) antigen as gangliosides containing n-glycolylneuraminic acid, Int Arch Allergy Appl Immunol., 57, 477, 10.1159/000232140 · DOI · Paper page
  9. Schauer, 1968, On biosynthesis of the glycolyl groups of N-glycolylneuraminic acid Oxidative conversion of N-acetyl groups to glycolyl groups, Hoppe Seylers Z Physiol Chem., 349, 645, 10.1515/bchm2.1968.349.1.645 · DOI
  10. Shaw, 1988, The biosynthesis of N-glycoloylneuraminic acid occurs by hydroxylation of the CMP-glycoside of N-acetylneuraminic acid, Biol Chem Hoppe Seyler., 369, 477, 10.1515/bchm3.1988.369.1.477 · DOI · Paper page
  11. Muchmore, 1989, Biosynthesis of N-glycolyneuraminic acid. The primary site of hydroxylation of N-acetylneuraminic acid is the cytosolic sugar nucleotide pool, J Biol Chem., 264, 20216, 10.1016/S0021-9258(19)47049-X · DOI · Paper page
  12. Kozutsumi, 1990, Participation of cytochrome b5 in CMP-N-acetylneuraminic acid hydroxylation in mouse liver cytosol, J Biochem., 108, 704, 10.1093/oxfordjournals.jbchem.a123268 · DOI · Paper page
  13. Kozutsumi, 1991, Reconstitution of CMP-N-acetylneuraminic acid hydroxylation activity using a mouse liver cytosol fraction and soluble cytochrome b5 purified from horse erythrocytes, J Biochem., 110, 429, 10.1093/oxfordjournals.jbchem.a123598 · DOI · Paper page
  14. Nishimaki, 1978, Studies on heterophile antibodies in rheumatoid arthritis, Arthritis Rheum., 21, 634, 10.1002/art.1780210604 · DOI
  15. Nishimaki, 1978, Studies on immune complexes in rheumatoid arthritis, Arthritis Rheum., 21, 639, 10.1002/art.1780210605 · DOI
  16. Nishimaki, 1979, Hanganutziu-Deicher antigen and antibody in pathologic sera and tissues, J Immunol., 122, 2314, 10.4049/jimmunol.122.6.2314 · DOI · Paper page
  17. Morito, 1982, Hanganutziu-deicher antibodies in infectious mononucleosis and other diseases, J Immunol., 129, 2524, 10.4049/jimmunol.129.6.2524 · DOI · Paper page
  18. Ikuta, 1982, Hanganutziu-Deicher type-heterophile antigen-positive cells in human cancer tissues demonstrated by membrane immunofluorescence, Biken J., 25, 47
  19. Arita, 1982, Heterophile Hanganutziu-deicher antibodies in sera of patients with kawasaki diseases, Biken J., 25, 157
  20. Takiguchi, 1984, Immunological studies on Kawasaki disease. I. Appearance of Hanganutziu-Deicher antibodies, Clin Exp Immunol., 56, 345
  21. Mukuria, 1986, A specific enzyme-linked immunosorbent assay (ELISA) procedure for detection of heterophile Hanganutziu and Deicher (HD) antibodies, J Immunol Methods., 86, 179, 10.1016/0022-1759(86)90450-3 · DOI
  22. Morito, 1986, Studies on Hanganutziu-Deicher antigens-antibodies. I. Hanganutziu-Deicher antibodies of IgG class in liver diseases, Int Arch Allergy Appl Immunol., 81, 204, 10.1159/000234135 · DOI · Paper page
  23. Nakarai, 1987, Expression of heterophile, Paul-Bunnell and Hanganutziu-Deicher antigens on human melanoma cell lines, Int Arch Allergy Appl Immunol., 83, 160, 10.1159/000234349 · DOI
  24. Higashihara, 1991, Survey of Hanganutziu and Deicher antibodies in operated patients, Int Arch Allergy Appl Immunol., 95, 231, 10.1159/000235434 · DOI · Paper page
  25. Higashi, 1984, Tumor-associated expression of glycosphingolipid Hanganutziu-Deicher antigen in human cancers, Gann., 75, 1025
  26. Ohashi, 1983, Hanganutziu-Deicher heterophile antigen in human retinoblastoma cells, Am J Ophthalmol., 96, 321, 10.1016/S0002-9394(14)77822-5 · DOI
  27. Higashi, 1984, Sensitive enzyme-immunostaining and densitometric determination on thin-layer chromatography of N-glycolylneuraminic acid-containing glycosphingolipids, Hanganutziu-Deicher antigens, J Biochem, 95, 1517, 10.1093/oxfordjournals.jbchem.a134760 · DOI
  28. Mukuria, 1985, A potential radioimmunoassay system for detection of Hanganutziu-Deicher type heterophile antigen(s) and antibodies in tissues and fluids, J Immunol Methods., 80, 97, 10.1016/0022-1759(85)90168-1 · DOI
  29. Higashi, 1985, Characterization of N-glycolylneuraminic acid-containing gangliosides as tumor-associated Hanganutziu-Deicher antigen in human colon cancer, Cancer Res., 45, 3796
  30. Nowak, 1986, Interaction of bovine erythrocyte N-glycolylneuraminic acid-containing gangliosides and glycoproteins with a human Hanganutziu-Deicher serum, Mol Immunol., 23, 693, 10.1016/0161-5890(86)90079-9 · DOI
  31. Mukuria, 1986, Microstructure of the sialic acid moiety of N-glycolylneuraminyllactosylceramide and the elucidation of Hanganutziu and Deicher (HD) antigenicity, Immunol Lett., 12, 165, 10.1016/0165-2478(86)90100-8 · DOI
  32. Kawachi, 1988, Heterophile Hanganutziu-Deicher antigen in ganglioside fractions of human melanoma tissues, Int Arch Allergy Appl Immunol., 85, 381, 10.1159/000234536 · DOI
  33. Fukui, 1989, Detection of glycoproteins as tumor-associated Hanganutziu-Deicher antigen in human gastric cancer cell line, NUGC4, Biochem Biophys Res Commun., 160, 1149, 10.1016/S0006-291X(89)80123-8 · DOI
  34. Nakarai, 1990, Hanganutziu-Deicher antigen as a possible target for immunotherapy of melanoma, Int Arch Allergy Appl Immunol., 91, 323, 10.1159/000235135 · DOI
  35. Saida, 1990, Immunohistochemical detection of heterophile Hanganutziu-Deicher antigen in human malignant melanoma, Arch Dermatol Res., 282, 179, 10.1007/BF00372619 · DOI
  36. Diaz, 2009, Sensitive and specific detection of the non-human sialic acid N-glycolylneuraminic acid in human tissues and biotherapeutic products, PLoS ONE., 4, e4241, 10.1371/journal.pone.0004241 · DOI · Paper page
  37. Pham, 2009, Evidence for a novel human-specific xeno-auto-antibody response against vascular endothelium, Blood., 114, 5225, 10.1182/blood-2009-05-220400 · DOI · Paper page
  38. Irie, 1998, The molecular basis for the absence of N-glycolylneuraminic acid in humans, J Biol Chem., 273, 15866, 10.1074/jbc.273.25.15866 · DOI · Paper page
  39. Chou, 1998, A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence, Proc Natl Acad Sci USA., 95, 11751, 10.1073/pnas.95.20.11751 · DOI · Paper page
  40. Hayakawa, 2001, Alu-mediated inactivation of the human CMP- N-acetylneuraminic acid hydroxylase gene, Proc Natl Acad Sci USA., 98, 11399, 10.1073/pnas.191268198 · DOI · Paper page
  41. Chou, 2002, Inactivation of CMP-N-acetylneuraminic acid hydroxylase occurred prior to brain expansion during human evolution, Proc Natl Acad Sci USA., 99, 11736, 10.1073/pnas.182257399 · DOI · Paper page
  42. Muchmore, 1998, A structural difference between the cell surfaces of humans and the great apes, Am J Phys Anthropol., 107, 187, 10.1002/(SICI)1096-8644(199810)107:2<187::AID-AJPA5>3.0.CO;2-S · doi:10.1002/(sici)1096-8644(199810)107:2<187::aid-ajpa5>3.0.co;2-s
  43. Bergfeld, 2017, N-glycolyl groups of nonhuman chondroitin sulfates survive in ancient fossils, Proc Natl Acad Sci USA., 114, E8155, 10.1073/pnas.1706306114 · DOI
  44. Ma, 2016, A mouse model for dietary xenosialitis: antibodies to xenoglycan can reduce fertility, J Biol Chem., 291, 18222, 10.1074/jbc.M116.739169 · DOI
  45. Schauer, 2009, Low incidence of N-glycolylneuraminic acid in birds and reptiles and its absence in the platypus, Carbohydr Res., 344, 1494, 10.1016/j.carres.2009.05.020 · DOI
  46. Peri, 2018, Phylogenetic distribution of CMP-Neu5Ac hydroxylase (CMAH), the enzyme synthetizing the proinflammatory human xenoantigen Neu5Gc, Genome Biol Evol., 10, 207, 10.1093/gbe/evx251 · DOI · Paper page
  47. Hedlund, 2008, Evidence for a human-specific mechanism for diet and antibody-mediated inflammation in carcinoma progression, Proc Natl Acad Sci USA., 105, 18936, 10.1073/pnas.0803943105 · DOI · Paper page
  48. Oetke, 2001, Evidence for efficient uptake and incorporation of sialic acid by eukaryotic cells, Eur J Biochem., 268, 4553, 10.1046/j.1432-1327.2001.02379.x · DOI · Paper page
  49. Hedlund, 2007, N-glycolylneuraminic acid deficiency in mice: implications for human biology and evolution, Mol Cell Biol., 27, 4340, 10.1128/MCB.00379-07 · DOI · Paper page
  50. Samraj, 2015, A red meat-derived glycan promotes inflammation and cancer progression, Proc Natl Acad Sci USA., 112, 542, 10.1073/pnas.1417508112 · DOI · Paper page
  51. Schauer, 1982, Chemistry, metabolism, and biological functions of sialic acids, Adv Carbohydr Chem Biochem., 40, 131, 10.1016/S0065-2318(08)60109-2 · DOI · Paper page
  52. Warren, 1963, The distribution of sialic acids in nature, Comp Biochem Physiol., 10, 153, 10.1016/0010-406X(63)90238-X · DOI · Paper page
  53. Malykh, 1999, The presence of N-acetylneuraminic acid in Malpighian tubules of larvae of the cicada Philaenus spumarius, Glycoconjugate J., 16, 731, 10.1023/A:1007115627708 · doi:10.1023/a:1007115627708
  54. Roth, 1992, Occurrence of sialic acids in Drosophila melanogaster, Science., 256, 673, 10.1126/science.1585182 · doi:10.1126/science.1585182
  55. Schauer, 2018, Exploration of the sialic acid world, Adv Carbohydr Chem Biochem., 75, 1, 10.1016/bs.accb.2018.09.001 · DOI · Paper page
  56. Wang, 2012, Molecular mechanism underlying sialic acid as an essential nutrient for brain development and cognition, Adv Nutr., 3, 465S, 10.3945/an.112.001875 · DOI · Paper page
  57. Chen, 2013, LC-MS/MS quantification of N-acetylneuraminic acid, N-glycolylneuraminic acid and ketodeoxynonulosonic acid levels in the urine and potential relationship with dietary sialic acid intake and disease in 3- to 5-year-old children, Br J Nutr., 111, 1, 10.1017/S0007114513002468 · DOI
  58. Padler-Karavani, 2008, Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease, Glycobiology., 18, 818, 10.1093/glycob/cwn072 · DOI · Paper page
  59. Banda, 2012, Metabolism of vertebrate amino sugars with N-glycolyl groups: mechanisms underlying gastrointestinal incorporation of the non-human sialic acid xeno-autoantigen N-glycolylneuraminic acid, J Biol Chem., 287, 28852, 10.1074/jbc.M112.364182 · DOI · Paper page
  60. Nöhle, 1984, Metabolism of sialic acids from exogenously administered sialyllactose and mucin in mouse and rat, Hoppe Seylers Z Physiol Chem., 365, 1457, 10.1515/bchm2.1984.365.2.1457 · DOI
  61. Bardor, 2005, Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells, J Biol Chem., 280, 4228, 10.1074/jbc.M412040200 · DOI · Paper page
  62. Kabat, 1988, The epitope associated with the binding of the capsular polysaccharide of the group B meningococcus and of Escherichia coli K1 to a human monoclonal macroglobulin, IgMNOV, J Exp Med., 168, 699, 10.1084/jem.168.2.699 · DOI
  63. Frei, 2018, Exposure to nonmicrobial N-glycolylneuraminic acid protects farmers' children against airway inflammation and colitis, J Allergy Clin Immunol., 141, 382, 10.1016/j.jaci.2017.04.051 · DOI
  64. Bergfeld, 2012, Metabolism of vertebrate amino sugars with N-glycolyl groups: elucidating the intracellular fate of the non-human sialic acid N-glycolylneuraminic acid, J Biol Chem., 287, 28865, 10.1074/jbc.M112.363549 · DOI · Paper page
  65. Clausen, 2016, Oncofetal chondroitin sulfate glycosaminoglycans are key players in integrin signaling and tumor cell motility, Mol Cancer Res., 14, 1288, 10.1158/1541-7786.MCR-16-0103 · DOI
  66. Agerbaek, 2017, Burkitt lymphoma expresses oncofetal chondroitin sulfate without being a reservoir for placental malaria sequestration, Int J Cancer., 140, 1597, 10.1002/ijc.30575 · DOI
  67. Agerbæk, 2018, Fighting cancer using an oncofetal glycosaminoglycan-binding protein from malaria parasites, Trends Parasitol., 35, 178, 10.1016/j.pt.2018.11.004 · DOI
  68. Agerbæk, 2018, The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent manner, Nat Commun., 9, 3279, 10.1038/s41467-018-05793-2 · DOI · Paper page
  69. Zhu, 2002, Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum, Xenotransplantation., 9, 376, 10.1034/j.1399-3089.2002.02138.x · DOI · Paper page
  70. Nguyen, 2005, Effects of natural human antibodies against a nonhuman sialic acid that metabolically incorporates into activated and malignant immune cells, J Immunol., 175, 228, 10.4049/jimmunol.175.1.228 · DOI · Paper page
  71. Tahara, 2010, Immunological property of antibodies against N-glycolylneuraminic acid epitopes in cytidine monophospho-N-acetylneuraminic acid hydroxylase-deficient mice, J Immunol., 184, 3269, 10.4049/jimmunol.0902857 · DOI · Paper page
  72. Taylor, 2010, Novel mechanism for the generation of human xeno-autoantibodies against the nonhuman sialic acid N-glycolylneuraminic acid, J Exp Med., 207, 1637, 10.1084/jem.20100575 · DOI · Paper page
  73. Ochsenbein, 2000, Natural antibodies and complement link innate and acquired immunity, Immunol Today., 21, 624, 10.1016/S0167-5699(00)01754-0 · DOI · Paper page
  74. Lu, 2012, LC-MS analysis of polyclonal human anti-Neu5Gc xeno-autoantibodies immunoglobulin G Subclass and partial sequence using multistep intravenous immunoglobulin affinity purification and multienzymatic digestion, Anal Chem., 84, 2761, 10.1021/ac2030893 · DOI
  75. Naito, 2007, Germinal center marker GL7 probes activation-dependent repression of N-glycolylneuraminic acid, a sialic acid species involved in the negative modulation of B-cell activation, Mol Cell Biol., 27, 3008, 10.1128/MCB.02047-06 · DOI · Paper page
  76. Cariappa, 2009, B cell antigen receptor signal strength and peripheral B cell development are regulated by a 9-O-acetyl sialic acid esterase, J Exp Med., 206, 125, 10.1084/jem.20081399 · DOI · Paper page
  77. Azuma, 1970, Occurrence of N-glycolylmuramic acid in bacterial cell walls. A preliminary survey, Biochim Biophys Acta., 208, 444, 10.1016/0304-4165(70)90217-5 · DOI
  78. Essers, 1978, Evidence for the incorporation of molecular oxygen, a pathway in biosynthesis of N-glycolylmuramic acid in Mycobacterium phlei, Biochim Biophys Acta., 544, 180, 10.1016/0304-4165(78)90221-0 · doi:10.1016/0304-4165(78)90221-0
  79. Raymond, 2005, Identification of the namH gene, encoding the hydroxylase responsible for the N-glycolylation of the mycobacterial peptidoglycan, J Biol Chem., 280, 326, 10.1074/jbc.M411006200 · DOI · Paper page
  80. Mahapatra, 2008, Unique structural features of the peptidoglycan of Mycobacterium leprae, J Bacteriol., 190, 655, 10.1128/JB.00982-07 · DOI · Paper page
  81. Coulombe, 2009, Increased NOD2-mediated recognition of N-glycolyl muramyl dipeptide, J Exp Med., 206, 1709, 10.1084/jem.20081779 · DOI · Paper page
  82. Daryaee, 2009, Synthesis and evaluation of in vitro anti-tuberculosis activity of N-substituted glycolamides, Eur J Med Chem., 44, 289, 10.1016/j.ejmech.2008.02.022 · DOI
  83. Vamecq, 1990, Studies on the metabolism of glycolyl-CoA, Biochem Cell Biol., 68, 846, 10.1139/o90-125 · DOI
  84. Vamecq, 1992, Subcellular distribution of glycolyltransferases in rodent liver and their significance in special reference to the synthesis of N-glycolyneuraminic acid, J Biochem., 111, 579, 10.1093/oxfordjournals.jbchem.a123800 · DOI
  85. Wang, 1993, Modeling study of antibody combining sites to (α1-6)dextrans. Predictions of the conformational contribution of VL-CDR3 and Jkappa segments to groove-type combining sites, J Biol Chem., 268, 20584, 10.1016/S0021-9258(20)80765-0 · DOI
  86. Klebert, 1993, Primary structure of the murine monoclonal IgG2a antibody mAb735 against (2-8) polysialic acid, Biol Chem Hoppe Seyler., 374, 993, 10.1515/bchm3.1993.374.7-12.993 · doi:10.1515/bchm3.1993.374.7-12.993
  87. Eleftheriou, 2014, Prevalence of anti-Neu5Gc antibodies in patients with hypothyroidism, Biomed Res Int., 2014, 963230, 10.1155/2014/963230 · DOI
  88. Hurh, 2016, Human antibody reactivity against xenogeneic N-glycolylneuraminic acid and galactose-α-1,3-galactose antigen, Xenotransplantation., 23, 279, 10.1111/xen.12239 · DOI
  89. Gong, 2018, Immunochromatographic strip biosensor for the rapid detection of N-glycolylneuraminic acid based on aptamer-conjugated nanoparticle, Anal Biochem., 2, 52, 10.1016/j.ab.2018.07.017 · DOI
  90. Padler-Karavani, 2011, Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer, Cancer Res., 71, 3352, 10.1158/0008-5472.CAN-10-4102 · DOI · Paper page
  91. Samraj, 2018, Polyclonal human antibodies against glycans bearing red meat-derived non-human sialic acid N-glycolylneuraminic acid are stable, reproducible, complex and vary between individuals: Total antibody levels are associated with colorectal cancer risk, PLoS ONE., 13, e0197464, 10.1371/journal.pone.0197464 · DOI · Paper page
  92. Bashir, 2018, Presentation mode of glycans affect recognition of human serum anti-Neu5Gc IgG antibodies, Bioconjug Chem., 30, 161, 10.1021/acs.bioconjchem.8b00817 · DOI
  93. Apicella, 2012, Nontypeable Haemophilus influenzae: the role of N-acetyl-5-neuraminic acid in biology, Front Cell Infect Microbiol., 2, 19, 10.3389/fcimb.2012.00019 · DOI
  94. Carr, 2002, In vivo and in vitro anti-tumor effect of 14F7 monoclonal antibody, Hybrid Hybridomics., 21, 463, 10.1089/153685902321043990 · doi:10.1089/153685902321043990
  95. Rodríguez, 2003, Generation and characterization of an anti-idiotype monoclonal antibody related to GM3(NeuGc) ganglioside, Hybrid Hybridomics., 22, 307, 10.1089/153685903322538836 · doi:10.1089/153685903322538836
  96. Díaz, 2003, Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides, Clin Immunol., 107, 80, 10.1016/S1521-6616(03)00036-6 · doi:10.1016/s1521-6616(03)00036-6
  97. Hernández, 2005, Generation of anti-Neu-glycolyl-ganglioside antibodies by immunization with an anti-idiotype monoclonal antibody: a self versus non-self-matter, Immunobiology., 210, 11, 10.1089/153685903322328947 · doi:10.1089/153685903322328947
  98. Leon, 2005, Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells, Cancer Immunol Immunother., 55, 443, 10.1007/s00262-005-0041-6 · doi:10.1007/s00262-005-0041-6
  99. Oliva, 2006, Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99m)Tc, Breast Cancer Res Treat., 96, 115, 10.1007/s10549-005-9064-0 · doi:10.1007/s10549-005-9064-0
  100. Neninger, 2007, Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial, Cancer Biol Ther., 6, 145, 10.4161/cbt.6.2.3574 · doi:10.4161/cbt.6.2.3574
  101. Labrada, 2010, Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy, Expert Opin Biol Ther., 10, 153, 10.1517/14712590903443084 · DOI
  102. Fernandez, 2010, NGcGM3 ganglioside: a privileged target for cancer vaccines, Clin Dev Immunol., 2010, 814397, 10.1155/2010/814397 · DOI
  103. Vázquez, 2012, Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data, Front Oncol., 2, 150, 10.3389/fonc.2012.00150 · DOI
  104. Blanco, 2013, Immunoreactivity of the 14F7 Mab raised against N-glycolyl GM3 ganglioside in primary lymphoid tumors and lymph node metastasis, Patholog Res Int., 2013, 920972, 10.1155/2013/920972 · DOI
  105. Blanco, 2013, Tissue Reactivity of the 14F7 mab raised against n-glycolyl GM3 ganglioside in tumors of neuroectodermal, mesodermal, and epithelial origin, J Biomark., 2013, 602417, 10.1155/2013/602417 · DOI
  106. Palomo, 2016, Frequent co-expression of EGFR and NeuGcGM3 ganglioside in cancer: it's potential therapeutic implications, Clin Exp Metastasis., 33, 717, 10.1007/s10585-016-9811-0 · DOI
  107. Labrada, 2018, GM3(Neu5Gc) ganglioside: an evolution fixed neoantigen for cancer immunotherapy, Semin Oncol., 45, 41, 10.1053/j.seminoncol.2018.04.003 · DOI
  108. de, 2014, Cancer vaccine characterization: from bench to clinic, Vaccine., 32, 2851, 10.1016/j.vaccine.2014.02.017 · DOI
  109. Gajdosik, 2014, Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer, Drugs Today., 50, 301, 10.1358/dot.2014.50.4.2116670 · doi:10.1358/dot.2014.50.4.2116670
  110. Bousquet, 2018, Hypothesis: hypoxia induces de novo synthesis of NeuGc gangliosides in humans through CMAH domain substitute, Biochem Biophys Res Commun., 495, 1562, 10.1016/j.bbrc.2017.11.183 · DOI
  111. Bada, 2002, Toxicity of a GM3 cancer vaccine in Macaca fascicularis monkey: a 12-month study, Hum Exp Toxicol., 21, 263, 10.1191/0960327102ht248oa · doi:10.1191/0960327102ht248oa
  112. Amon, 2017, Glycan microarray reveal induced IgGs repertoire shift against a dietary carbohydrate in response to rabbit anti-human thymocyte therapy, Oncotarget., 8, 112236, 10.18632/oncotarget.23096 · DOI
  113. Couvrat-Desvergnes, 2015, Rabbit antithymocyte globulin-induced serum sickness disease and human kidney graft survival, J Clin Invest., 125, 4655, 10.1172/JCI82267 · DOI · Paper page
  114. Okamura, 2007, Immunological properties of human embryonic stem cell-derived oligodendrocyte progenitor cells, J Neuroimmunol., 192, 134, 10.1016/j.jneuroim.2007.09.030 · DOI
  115. Salama, 2017, Anti-Gal and Anti-Neu5Gc responses in nonimmunosuppressed patients after treatment with rabbit antithymocyte polyclonal IgGs, Transplantation., 101, 2501, 10.1097/TP.0000000000001686 · DOI
  116. Pearce, 2014, Hormesis in cancer immunology: does the quantity of an immune reactant matter, Oncoimmunology., 3, e29312, 10.4161/onci.29312 · DOI
  117. Pearce, 2014, Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies, Proc Natl Acad Sci USA., 111, 5998, 10.1073/pnas.1209067111 · DOI · Paper page
  118. Marquina, 1996, Gangliosides expressed in human breast cancer, Cancer Res., 56, 5165
  119. Carr, 2000, A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors, Hybridoma., 19, 241, 10.1089/02724570050109639 · DOI
  120. Giovannucci, 1994, Intake of fat, meat, and fiber in relation to risk of colon cancer in men, Cancer Res., 54, 2390
  121. Stavric, 1994, Biological significance of trace levels of mutagenic heterocyclic aromatic amines in human diet: a critical review, Food Chem Toxicol., 32, 977, 10.1016/0278-6915(94)90093-0 · DOI
  122. Santarelli, 2008, Processed meat and colorectal cancer: a review of epidemiologic and experimental evidence, Nutr Cancer., 60, 131, 10.1080/01635580701684872 · DOI · Paper page
  123. Lamberto, 2014, Mycovirus-like DNA virus sequences from cattle serum and human brain and serum samples from multiple sclerosis patients, Genome Announc., 2, e00848, 10.1128/genomeA.00848-14 · DOI
  124. Zur Hausen, 2017, Infectious agents in bovine red meat and milk and their potential role in cancer and other chronic diseases, Curr Top Microbiol Immunol., 407, 83, 10.1007/82_2017_3 · DOI
  125. Falida, 2017, Isolation of two virus-like circular DNAs from commercially available milk samples, Genome Announc., 5, e00266, 10.1128/genomeA.00266-17 · doi:10.1128/genomea.00266-17
  126. Zur Hausen, 2018, Specific nutritional infections early in life as risk factors for human colon and breast cancers several decades later, Int J Cancer., 144, 1574, 10.1002/ijc.31882 · DOI
  127. Coussens, 2013, Neutralizing tumor-promoting chronic inflammation: a magic bullet?, Science, 339, 286, 10.1126/science.1232227 · DOI · Paper page
  128. Balkwill, 2001, Inflammation and cancer: back to Virchow?, Lancet., 357, 539, 10.1016/S0140-6736(00)04046-0 · DOI · Paper page
  129. Grivennikov, 2010, Immunity, inflammation, and cancer, Cell., 140, 883, 10.1016/j.cell.2010.01.025 · DOI · Paper page
  130. Hanahan, 2011, Hallmarks of cancer: the next generation, Cell., 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
  131. Mantovani, 2008, Cancer-related inflammation, Nature., 454, 436, 10.1038/nature07205 · DOI · Paper page
  132. Wang, 2007, Inflammatory mediators and nuclear receptor signaling in colorectal cancer, Cell Cycle., 6, 682, 10.4161/cc.6.6.4030 · DOI · Paper page
  133. Yin, 2006, Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells, Cancer Res., 66, 2937, 10.1158/0008-5472.CAN-05-2615 · DOI · Paper page
  134. Hedlund, 2008, alpha 2-6-Linked sialic acids on N-glycans modulate carcinoma differentiation in vivo, Cancer Res., 68, 388, 10.1158/0008-5472.CAN-07-1340 · DOI · Paper page
  135. Soulillou, 2018, No increase in Colon cancer risk following induction with Neu5Gc-bearing rabbit Anti-T Cell IgG (ATG) in recipients of kidney transplants, Cancers., 10, E324, 10.3390/cancers10090324 · DOI
  136. Grundy, 1999, Diabetes and cardiovascular disease: a statement for healthcare professionals from the American heart association, Circulation., 100, 1134, 10.1161/01.CIR.100.10.1134 · DOI · Paper page
  137. Varki, 2009, Heart disease is common in humans and chimpanzees, but is caused by different pathological processes, Evol Appl., 2, 101, 10.1111/j.1752-4571.2008.00064.x · DOI · Paper page
  138. Swirski, 2013, Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure, Science., 339, 161, 10.1126/science.1230719 · DOI · Paper page
  139. Balla, 1991, Hemin: a possible physiological mediator of low density lipoprotein oxidation and endothelial injury, Arterioscler Thromb., 11, 1700, 10.1161/01.ATV.11.6.1700 · DOI · Paper page
  140. Balla, 1993, Oxidized low-density lipoproteins and endothelium: oral vitamin E supplementation prevents oxidized low-density lipoprotein-mediated vascular injury, Trans Assoc Am Phys., 106, 128
  141. Belcher, 1993, Vitamin E, LDL, and endothelium. Brief oral vitamin supplementation prevents oxidized LDL-mediated vascular injury in vitro, Arterioscler Thromb., 13, 1779, 10.1161/01.ATV.13.12.1779 · DOI · Paper page
  142. Nagy, 2010, Red cells, hemoglobin, heme, iron, and atherogenesis, Arterioscler Thromb Vasc Biol., 30, 1347, 10.1161/ATVBAHA.110.206433 · DOI · Paper page
  143. Rabinovich, 2012, Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer, Immunity., 36, 322, 10.1016/j.immuni.2012.03.004 · DOI · Paper page
  144. Fuster, 2005, The sweet and sour of cancer: glycans as novel therapeutic targets, Nat Rev Cancer., 5, 526, 10.1038/nrc1649 · DOI · Paper page
  145. Yonezawa, 1992, Sialosyl-Tn antigen: Its distribution in normal human tissues and expression in adenocarcinomas, Am J Clin Pathol., 98, 167, 10.1093/ajcp/98.2.167 · DOI
  146. Ogata, 1998, Different modes of sialyl-Tn expression during malignant transformation of human colonic mucosa, Glycoconj J., 15, 29, 10.1023/A:1006935331756 · DOI
  147. Kobayashi, 1992, Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer, J Clin Oncol., 10, 95, 10.1200/JCO.1992.10.1.95 · DOI · Paper page
  148. Imai, 2001, Immunohistochemical expression of T, Tn and sialyl-Tn antigens and clinical outcome in human breast carcinoma, Anticancer Res., 21, 1327
  149. Kim, 2002, Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas, Gastroenterology., 123, 1052, 10.1053/gast.2002.36018 · DOI · Paper page
  150. Conze, 2010, MUC2 mucin is a major carrier of the cancer-associated sialyl-Tn antigen in intestinal metaplasia and gastric carcinomas, Glycobiology., 20, 199, 10.1093/glycob/cwp161 · DOI
  151. Cao, 1996, Thomsen-Friedenreich-related carbohydrate antigens in normal adult human tissues: a systematic and comparative study, Histochem Cell Biol., 106, 197, 10.1007/BF02484401 · DOI · Paper page
  152. Starbuck, 2018, Treatment of ovarian cancer by targeting the tumor stem cell-associated carbohydrate antigen, Sialyl-Thomsen-nouveau, Oncotarget., 9, 23289, 10.18632/oncotarget.25289 · DOI
  153. Eavarone, 2018, Humanized anti-Sialyl-Tn antibodies for the treatment of ovarian carcinoma, PLoS ONE., 13, e0201314, 10.1371/journal.pone.0201314 · DOI
  154. Carr, 2003, Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine, J Clin Oncol., 21, 1015, 10.1200/JCO.2003.02.124 · DOI
  155. Fernández-Marrero, 2011, Fernandez- A cytotoxic humanized anti-ganglioside antibody produced in a murine cell line defective of N-glycolylated-glycoconjugates, Immunobiology., 216, 1239, 10.1016/j.imbio.2011.07.004 · DOI
  156. Hernández, 2008, Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody, J Immunol., 181, 6625, 10.4049/jimmunol.181.9.6625 · DOI · Paper page
  157. Segatori, 2018, Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients, Cancer Immunol Immunother., 67, 1285, 10.1007/s00262-018-2188-y · DOI
  158. Scursoni, 2010, Detection and characterization of N-glycolyated gangliosides in wilms tumor by immunohistochemistry, Pediatr Dev Pathol., 13, 18, 10.2350/08-10-0544.1 · DOI
  159. Scursoni, 2011, Detection of N-glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: an attractive vaccine target for aggressive pediatric cancer, Clin Dev Immunol., 2011, 245181, 10.1155/2011/245181 · DOI
  160. Blanco, 2011, Immunohistochemical reactivity of the 14F7 monoclonal antibody raised against N-Glycolyl GM3 ganglioside in some benign and malignant skin neoplasms, ISRN Dermatol., 2011, 848909, 10.5402/2011/848909 · DOI
  161. Blanco, 2011, Immunoreactivity of the 14F7 mab raised against N-Glycolyl GM3 ganglioside in epithelial malignant tumors from digestive system, ISRN Gastroenterol., 2011, 645641, 10.5402/2011/645641 · DOI
  162. Blanco, 2012, Immunoreactivity of the 14F7 Mab (raised AGAINST N-Glycolyl Gm3 ganglioside) as a positive prognostic factor in non-small-cell lung cancer, Patholog Res Int., 2012, 235418, 10.1155/2012/235418 · DOI
  163. Leviatan, 2017, Profiling anti-Neu5Gc IgG in human sera with a sialoglycan microarray assay, J Vis Exp., 125, e56094, 10.3791/56094 · DOI
  164. Amon, 2018, A combined computational-experimental approach to define the structural origin of antibody recognition of sialyl-Tn, a tumor-associated carbohydrate antigen, Sci Rep., 8, 10786, 10.1038/s41598-018-29209-9 · DOI
  165. Sliwkowski, 2013, Antibody therapeutics in cancer, Science., 341, 1192, 10.1126/science.1241145 · DOI · Paper page
  166. Bandera, 2007, Consumption of animal foods and endometrial cancer risk: a systematic literature review and meta-analysis, Cancer Causes Control., 18, 967, 10.1007/s10552-007-9038-0 · DOI
  167. Wallace, 2009, The association of lifestyle and dietary factors with the risk for serrated polyps of the colorectum, Cancer Epidemiol Biomarkers Prev., 18, 2310, 10.1158/1055-9965.EPI-09-0211 · DOI · Paper page
  168. McCullough, 2013, Association between red and processed meat intake and mortality among colorectal cancer survivors, J Clin Oncol., 31, 2773, 10.1200/JCO.2013.49.1126 · DOI
  169. Kim, 2018, Meat consumption and risk of metabolic syndrome: results from the Korean population and a meta-analysis of observational studies, Nutrients., 10, 10.3390/nu10040390 · DOI · Paper page
  170. Ludwig, 2005, Biomarkers in cancer staging, prognosis and treatment selection, Nat Rev Cancer., 5, 845, 10.1038/nrc1739 · DOI · Paper page
  171. Tan, 2009, Serum autoantibodies as biomarkers for early cancer detection, FEBS J., 276, 6880, 10.1111/j.1742-4658.2009.07396.x · DOI · Paper page
  172. Soussi, 2000, p53 Antibodies in the sera of patients with various types of cancer: a review, Cancer Res., 60, 1777
  173. Padler-Karavani, 2013, A simple method for assessment of human anti-Neu5Gc antibodies applied to Kawasaki disease, PLoS ONE., 8, e58443, 10.1371/journal.pone.0058443 · DOI · Paper page
  174. Choo, 2018, Food sources of fructose-containing sugars and glycaemic control: systematic review and meta-analysis of controlled intervention studies, BMJ., 363, k4644, 10.1136/bmj.k4644 · DOI · Paper page
  175. Ludwig, 2018, Dietary carbohydrates: role of quality and quantity in chronic disease, BMJ., 361, k2340, 10.1136/bmj.k2340 · DOI · Paper page

Cited by

See all 123

Metadata

Authors
Dhar, C., Sasmal, A., & Varki, A.
Venue
Frontiers in Immunology
Published
2019-04-17
Volume
10
ISSN
1664-3224
Cited by
123
References
24

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.